All the news Showing 10 of 24 articles from: Antiviral therapyGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources China National Medical Products Administration (NMPA) Approves Gilead’s Vemlidy® (Tenofovir Alafenamide) for Chronic Hepatitis B Virus (HBV) Infection Gilead press release / 20 November 2018 Janssen Announces Exclusive, Worldwide License Agreement With Arrowhead Pharmaceuticals to Develop and Commercialize a New Treatment for Chronic Hepatitis B Viral Infection Janssen press release / 05 October 2018 Arrowhead Presents New ARO-HBV Clinical Data Demonstrating HBsAg Reductions at World Gastroenterologists Summit Arrowhead / 07 September 2018 'Virus-cracking' molecules advance fight against hepatitis B Science Daily / 07 February 2018 European Commission Grants Marketing Authorization for Gilead’s Vemlidy® (Tenofovir Alafenamide, TAF) for the Treatment of Chronic Hepatitis B Virus Infection Gilead press release / 11 January 2017 U.S. Food and Drug Administration Approves Gilead’s Vemlidy® (Tenofovir Alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection Gilead press release / 11 November 2016 HBV drug Tyzeka discontinued Healio Hepatology / 11 October 2016 ContraVir Reports New CRV431 Data Highlighting Synergistic Activity with CMX157 Against Hepatitis B ContraVir press release / 12 September 2016 Antiviral therapy prolongs survival in immune tolerant hepatitis B patients Eurekalert Inf Dis / 15 April 2016 Treatment for chronic hepatitis B linked to increased rates of colorectal and cervical cancer EASL press release / 15 April 2016 ← First123Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E NAFLD Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Noticeboard Email bulletins News feeds